BIOLASE Future Growth
Future criteria checks 0/6
BIOLASE is forecast to grow earnings and revenue by 95.2% and 6.5% per annum respectively while EPS is expected to grow by 104.8% per annum.
Key information
95.2%
Earnings growth rate
104.8%
EPS growth rate
Medical Equipment earnings growth | 16.7% |
Revenue growth rate | 6.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Jun 2024 |
Recent future growth updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?
Jul 14Biolase shares jump 11% after regaining Nasdaq compliance
Feb 04Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined
Feb 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 55 | -6 | N/A | 2 | 3 |
12/31/2024 | 51 | -11 | N/A | -6 | 3 |
3/31/2024 | 49 | -38 | -15 | -14 | N/A |
12/31/2023 | 49 | -38 | -15 | -14 | N/A |
9/30/2023 | 50 | -25 | -19 | -17 | N/A |
6/30/2023 | 51 | -29 | -25 | -21 | N/A |
3/31/2023 | 49 | -30 | -28 | -24 | N/A |
12/31/2022 | 48 | -29 | -30 | -27 | N/A |
9/30/2022 | 47 | -24 | -28 | -24 | N/A |
6/30/2022 | 44 | -19 | -22 | -21 | N/A |
3/31/2022 | 41 | -14 | -19 | -18 | N/A |
12/31/2021 | 39 | -17 | -17 | -17 | N/A |
9/30/2021 | 35 | -18 | -15 | -15 | N/A |
6/30/2021 | 32 | -32 | -14 | -13 | N/A |
3/31/2021 | 26 | -36 | -15 | -15 | N/A |
12/31/2020 | 23 | -34 | -13 | -13 | N/A |
9/30/2020 | 24 | -32 | -16 | -16 | N/A |
6/30/2020 | 27 | -20 | -16 | -15 | N/A |
3/31/2020 | 32 | -19 | -12 | -12 | N/A |
12/31/2019 | 38 | -18 | -13 | -13 | N/A |
9/30/2019 | 41 | -21 | -12 | -12 | N/A |
6/30/2019 | 43 | -20 | -13 | -12 | N/A |
3/31/2019 | 46 | -21 | -15 | -14 | N/A |
12/31/2018 | 46 | -22 | -15 | -14 | N/A |
9/30/2018 | 46 | -18 | -15 | -15 | N/A |
6/30/2018 | 46 | -18 | -16 | -16 | N/A |
3/31/2018 | 46 | -22 | -19 | -18 | N/A |
12/31/2017 | 47 | -21 | N/A | -18 | N/A |
9/30/2017 | 48 | -21 | N/A | -17 | N/A |
6/30/2017 | 50 | -22 | N/A | -15 | N/A |
3/31/2017 | 52 | -17 | N/A | -11 | N/A |
12/31/2016 | 52 | -18 | N/A | -11 | N/A |
9/30/2016 | 52 | -16 | N/A | -10 | N/A |
6/30/2016 | 50 | -16 | N/A | -13 | N/A |
3/31/2016 | 48 | -19 | N/A | -15 | N/A |
12/31/2015 | 48 | -20 | N/A | -18 | N/A |
9/30/2015 | 47 | -22 | N/A | -21 | N/A |
6/30/2015 | 48 | -20 | N/A | -24 | N/A |
3/31/2015 | 47 | -19 | N/A | -21 | N/A |
12/31/2014 | 47 | -19 | N/A | -16 | N/A |
9/30/2014 | 49 | -17 | N/A | -12 | N/A |
6/30/2014 | 49 | -18 | N/A | -7 | N/A |
3/31/2014 | 53 | -14 | N/A | -9 | N/A |
12/31/2013 | 56 | -11 | N/A | -9 | N/A |
9/30/2013 | 60 | -8 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOL's revenue (6.5% per year) is forecast to grow slower than the US market (8.6% per year).
High Growth Revenue: BIOL's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOL's Return on Equity is forecast to be high in 3 years time